サマリー

レポートのスコープ

この調査レポートは、2021年までの医薬品市場とその競争環境について詳細な分析を組み込んでいます。主要プレイヤー、競合情報、革新的な技術、企業プロファイルを詳細に考察しています。また、主要プレイヤーの最近の開発状況や製品ポートフォリオを調査し、市場における市場シェア分析やランキングを掲載しています。米国、欧州、日本などの地域における最近の規制に焦点を当てた規制環境分析も含まれています。

レポートには以下の内容が含まれています：

- 2021年に最も売れている医薬品の概要
- 医薬品上位50品目の収益予測と規制状況の評価
- 医薬品のアプリケーションの説明と医薬品の特許に関する情報
- 医薬品トップ50の詳細な企業プロファイル

ページTOPに戻る

目次

Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of Report
1.4 Methodology
1.4.1 Primary Data and Information Gathering
1.4.2 Secondary Data and Information Gathering
1.4.3 Market Revenue Forecasts
1.5 Analyst's Credentials
1.6 BCC Custom Research
1.7 Related BCC Research Reports
Chapter 2 Global Pharmaceutical Drug Market
2.1 Overview
2.2 Key Strategies of Major Pharmaceutical Drugs Manufacturers
2.2.1 Distribution Network
2.2.2 Trends
2.2.3 Mergers and Acquisitions
2.2.4 Recommendations
2.3 Key Developments of the Major Pharmaceutical Drugs Manufacturers
2.3.1 Mergers and Acquisitions
2.3.2 Agreements, Joint Ventures, Expansions, Divestments, and Investments
2.3.3 New Product Launches and Approvals
2.4 Long-Term Outlook
Chapter 3 Regulatory Structure: Pharmaceutical Drug Market
3.1 Regulatory Background
3.2 Regulatory Systems for Biopharmaceuticals by Region
3.2.1 U.S.
3.2.2 Europe
3.2.3 Japan
3.3 Regulatory Systems for Pharmaceuticals by Region
3.3.1 U.S.
3.3.2 Japan
3.3.3 India
3.3.4 Brazil
3.4 Regulations for Vaccines
3.4.1 Current Regulatory Issues for Vaccines
3.4.2 Moderna Vaccine Regulation in the U.K.
3.5 Key Regulatory Updates 2021
3.5.1 Pharmaceuticals
3.5.2 Medical Devices
3.6 Code of Federal Regulations (CFR)
3.7 Good Manufacturing Practice (GMP) Compliance
3.8 Establishment Registration
3.9 Drug Registration and Listing
3.10 Local Agent Requirements
3.10.1 Responsibilities of the U.S. agent
Chapter 4 Pricing and Reimbursement: Pharmaceuticals and Biologics
4.1 Pricing and Reimbursement Background
4.2 Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
4.2.1 U.S.
4.2.2 Europe
4.2.3 Japan
4.3 Pricing and Reimbursement Challenges for Pharmaceuticals
4.3.1 Patented Medicines Price
4.3.2 Prices of Older Drugs
Chapter 5 Company Profiles
ABBOTT
ABBVIE INC.
ALEXION PHARMACEUTICALS INC.
AMGEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
ASAHI KASEI CORP.
AUROBINDO PHARMA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
CHUGAI PHARMACEUTICAL CO. LTD.
CSL LTD.
DAIICHI SANKYO CO. LTD.
DR. REDDY'S LABORATORIES LTD.
EISAI CO. LTD.
ELI LILLY AND CO.
ENDO INTERNATIONAL PLC
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
H. LUNDBECK A/S
INCYTE
IPSEN PHARMA
JOHNSON & JOHNSON SERVICES INC.
MALLINCKRODT PLC
A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.
MERCK & CO. INC.
MERCK KGAA
MODERNA INC.
NOVARTIS AG
NOVO NORDISK A/S
OTSUKA HOLDINGS CO. LTD.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
F. HOFFMANN-LA ROCHE LTD. (ROCHE)
SANOFI
SERVIER LABORATORIES
SHANGHAI PHARMACEUTICALS HOLDING
SHIONOGI & CO. LTD.
CHINA NATIONAL PHARMACEUTICAL GROUP CORP. (SINOPHARM)
STADA ARZNEIMITTEL AG
SUMITOMO PHARMA CO. LTD
SUN PHARMACEUTICAL INDUSTRIES LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.
VERTEX PHARMACEUTICALS INC.
VIATRIS INC.
ZYDUS CADILA